Patents Assigned to Athersys, Inc.
-
Publication number: 20100310570Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.Type: ApplicationFiled: January 23, 2007Publication date: December 9, 2010Applicant: ATHERSYS, INC.Inventors: Robert Mays, Robert J. Deans, David C. Hess, James E. Carroll, Cesar V. Borlongan
-
Patent number: 7718647Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: GrantFiled: June 29, 2005Date of Patent: May 18, 2010Assignee: Athersys, Inc.Inventors: Youssef L. Bennani, Michael J. Robarge, David C. Bom, Norbert Varga, Lawrence N. Tumey
-
Publication number: 20100008890Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like with MAPCs, without the need for adjunctive immunosuppressive treatment.Type: ApplicationFiled: January 23, 2007Publication date: January 14, 2010Applicant: ATHERSYS, INC.Inventors: Robert W. Mays, Robert J. Deans
-
Patent number: 7528262Abstract: This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain indole derivatives and their salts and solvates. These compounds have H3 histamine receptor antagonist activity. This invention also relates to pharmaceutical compositions containing these compounds and to a method of treating disorders in which histamine H3 receptor blockade is beneficial.Type: GrantFiled: October 16, 2006Date of Patent: May 5, 2009Assignee: Athersys, Inc.Inventors: Youssef L. Bennani, Michael G. Campbell, David Dastrup, Emilie Porter Huck
-
Publication number: 20090104163Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.Type: ApplicationFiled: November 9, 2006Publication date: April 23, 2009Applicants: ATHERSYS, INC., OREGON HEALTH AND SCIENCE UNIVERSITYInventors: Robert Deans, Wouter Vant't Hof, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter
-
Publication number: 20080287465Abstract: Acrylic n-hydroxy imides and their use in pharmaceutical compositions and in the inhibition of flap endonuclease are disclosed.Type: ApplicationFiled: July 20, 2005Publication date: November 20, 2008Applicant: ATHERSYS, INC.Inventors: Lawrence N. Tumey, Youssef Bennani, Bayard Huck, David C. Bom
-
Patent number: 7423056Abstract: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for treating diseases, disorders, and conditions wherein modulation of the activity of serotonin receptors (5-HT) is desired (e.g. anxiety, depression and obesity).Type: GrantFiled: September 1, 2005Date of Patent: September 9, 2008Assignee: Athersys, Inc.Inventors: Youssef L. Bennani, David C. Bom, Michael J. Robarge
-
Patent number: 7319103Abstract: This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain non-imidazole tertiary amine derivatives and their salts and solvates. These compounds have H3 histamine receptor antagonist activity. This invention also relates to pharmaceutical compositions containing these compounds and to a method of treating disorders in which histamine H3 receptor blockade is beneficial.Type: GrantFiled: June 29, 2005Date of Patent: January 15, 2008Assignee: Athersys, Inc.Inventors: Youssef L. Bennani, James T. Anderson, Jianmin Wang, Michael G. Campbell
-
Patent number: 7316923Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. In another embodiment, the expression of the endogenous gene may be further increased by co-integration of one or more amplifiable markers, and selecting for increased copies of the one or more amplifiable markers located on the integrated vector. In another embodiment, the invention is directed to activation of endogenous genes by non-targeted integration of specialized activation vectors, which are provided by the invention, into the genome of a host cell.Type: GrantFiled: January 18, 2000Date of Patent: January 8, 2008Assignee: Athersys, Inc.Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett
-
Publication number: 20070178585Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.Type: ApplicationFiled: August 5, 2003Publication date: August 2, 2007Applicant: ATHERSYS, INC.Inventors: John Harrington, Bruce Sherf, Stephen Rundlett
-
Publication number: 20070122391Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.Type: ApplicationFiled: September 6, 2005Publication date: May 31, 2007Applicant: ATHERSYS, INC.Inventors: John Harrington, Bruce Sherf, Stephen Rundlett
-
Patent number: 7033782Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the sequence, structure, function, or expression profile of the genes.Type: GrantFiled: January 17, 2001Date of Patent: April 25, 2006Assignee: Athersys, Inc.Inventor: John J. Harrington
-
Publication number: 20050181502Abstract: The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.Type: ApplicationFiled: March 21, 2005Publication date: August 18, 2005Applicant: Athersys, Inc.Inventors: Leo Furcht, Catherine Verfaillie, Morayma Reyes
-
Patent number: 6897066Abstract: The field of the invention is activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention relates to expresssing an endogenous gene in a cell at levels higher than those normally found in the cell. Expression of the gene is activated or increased following integration, by non-homolgous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The method allows the identification and expression of gene undiscovered by current methods since no target sequence is necessary for integration. Thus, gene products associated with human disease and development are obtainable from gene that have not been sequenced and indeed, whose existence is unknown, as well as from well characterized genes. The methods provide gene products from such genes for therapeutic and diagnostic purposes. In one embodiment the vector comprises a promoter, an exon, and an unpaired splice donor sequence, the exon being derived from a eukaryotic gene.Type: GrantFiled: March 26, 1999Date of Patent: May 24, 2005Assignee: Athersys, Inc.Inventor: John J. Harrington
-
Publication number: 20040253591Abstract: The present invention is directed generally to reduction or inactivation of gene function or gene expression in cells in vitro and in multiorganisms. The invention encompasses methods for mutating cells using a combination of mutagens, particularly wherein at least one mutagen is an insertional mutagen, to achieve homozygous gene mutation or mutation of multiple genes required cumulatively to achieve a phenotype to create knock-outs, knock-downs, and other modifications in the same cell. The invention is also directed to cells (and libraries thereof) and organisms created by the methods of the invention, including those in which at least one of the genes created by insertional mutagenesis is tagged by means of the insertion sequences thereby allowing identification of the mutated gene(s). The invention is also directed to libraries of mutated cells and their uses.Type: ApplicationFiled: January 15, 2003Publication date: December 16, 2004Applicant: Athersys, Inc.Inventors: John Joseph Harrington , Paul David Jackson , Li Jiang
-
Publication number: 20040253727Abstract: The present invention is directed generally to reduction or inactivation of gene function or gene expression in cells in vitro and in multiorganisms. The invention encompasses methods for mutating cells using a combination of mutagens, particularly wherein at least one mutagen is an insertional mutagen, to achieve homozygous gene mutation or mutation of multiple genes required cumulatively to achieve a phenotype to create knock-outs, knock-downs, and other modifications in the same cell. The invention is also directed to cells (and libraries thereof) and organisms created by the methods of the invention, including those in which at least one of the genes created by insertional mutagenesis is tagged by means of the insertion sequences thereby allowing identification of the mutated gene(s). The invention is also directed to libraries of mutated cells and their uses.Type: ApplicationFiled: January 15, 2003Publication date: December 16, 2004Applicant: Athersys, Inc.Inventors: John Joseph Harrington , Paul David Jackson , Li Jiang
-
Publication number: 20040253589Abstract: The present invention is directed generally to reduction or inactivation of gene function or gene expression in cells in vitro and in multiorganisms. The invention encompasses methods for mutating cells using a combination of mutagens, particularly wherein at least one mutagen is an insertional mutagen, to achieve homozygous gene mutation or mutation of multiple genes required cumulatively to achieve a phenotype to create knock-outs, knock-downs, and other modifications in the same cell. The invention is also directed to cells (and libraries thereof) and organisms created by the methods of the invention, including those in which at least one of the genes created by insertional mutagenesis is tagged by means of the insertion sequences thereby allowing identification of the mutated gene(s). The invention is also directed to libraries of mutated cells and their uses.Type: ApplicationFiled: January 15, 2003Publication date: December 16, 2004Applicant: Athersys, Inc.Inventors: John Joseph Harrington , Paul David Jackson , Li Jiang
-
Publication number: 20040253590Abstract: The present invention is directed generally to reduction or inactivation of gene function or gene expression in cells in vitro and in multiorganisms. The invention encompasses methods for mutating cells using a combination of mutagens, particularly wherein at least one mutagen is an insertional mutagen, to achieve homozygous gene mutation or mutation of multiple genes required cumulatively to achieve a phenotype to create knock-outs, knock-downs, and other modifications in the same cell. The invention is also directed to cells (and libraries thereof) and organisms created by the methods of the invention, including those in which at least one of the genes created by insertional mutagenesis is tagged by means of the insertion sequences thereby allowing identification of the mutated gene(s). The invention is also directed to libraries of mutated cells and their uses.Type: ApplicationFiled: January 15, 2003Publication date: December 16, 2004Applicant: Athersys, Inc.Inventors: John Joseph Harrington , Paul David Jackson , Li Jiang
-
Publication number: 20040224378Abstract: The present invention relates to methods for using a human A Disintegrin And Metalloprotease containing ThromboSpondin repeats (ADAM-TS). The invention also relates to methods for using polynucleotides encoding the metalloprotease. The invention relates to methods using the ADAM-TS polypeptides and polynucleotides as a target for diagnosis and treatment in metalloprotease-mediated or -related disorders. The invention further relates to drug-screening methods using the ADAM-TS polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the ADAM-TS polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the ADAM-TS polypeptides and polynucleotides as a target. The invention further related to methods of treating a subject suffering from a ADAM-TS associated disorder.Type: ApplicationFiled: June 7, 2002Publication date: November 11, 2004Applicant: Athersys, Inc.Inventors: Paul David Jackson, Anthony Eugene Ting, Pieter W. Faber
-
Patent number: 6740503Abstract: The present invention is directed generally to activating gene expression or causing over-expression of a gene by recombination methods in situ. The invention also is directed generally to methods for expressing an endogenous gene in a cell at levels higher than those normally found in the cell. In one embodiment of the invention, expression of an endogenous gene is activated or increased following integration into the cell, by non-homologous or illegitimate recombination, of a regulatory sequence that activates expression of the gene. The invention also provides methods for the identification, activation, isolation, and/or expression of genes undiscoverable by current methods since no target sequence is necessary for integration. Thus, by the present invention, endogenous genes, including those associated with human disease and development, may be activated and isolated without prior knowledge of the, sequence, structure, function, or expression profile of the genes.Type: GrantFiled: January 18, 2000Date of Patent: May 25, 2004Assignee: Athersys, Inc.Inventors: John J. Harrington, Bruce Sherf, Stephen Rundlett